HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Corcept Therapeutics (NASDAQ:CORT) but has reduced the price target from $34 to $28.
January 02, 2024 | 6:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Corcept Therapeutics but lowers the price target from $34 to $28.
While the Buy rating indicates continued confidence in the company's fundamentals, the reduction in price target could suggest a reassessment of the company's near-term growth prospects or market conditions, potentially leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100